RecruitingNCT06724848

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population

A Translational Study in Patients With COPD and Pre-COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population


Sponsor

AstraZeneca

Enrollment

850 participants

Start Date

Jun 5, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on pre-COPD or PRISm, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants for 1-year period.


Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This study in Chinese patients examines biological markers (biomarkers) in people with established COPD (chronic obstructive pulmonary disease) and those in the early stages of lung damage, to better understand how the disease develops and predict outcomes. **You may be eligible if...** - Able to perform breathing function tests - Willing and able to follow the study protocol - Able to give informed consent **You may NOT be eligible if...** - Have a lung condition other than COPD that would confuse the results - Are currently a heavy smoker unwilling to participate in related assessments - Have recently had a serious respiratory infection or flare-up that has not resolved Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(14)

Research Site

Beijing, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Guangzhou, China

Research Site

Hefei, China

Research Site

Nanjing, China

Research Site

Nanning, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shenyang, China

Research Site

Wuhan, China

Research Site

Xuzhou, China

Research Site

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06724848


Related Trials